Zymedi
Korea - IncheonBiotechnology
Focus: Noncatalytic regulatory roles of aminoacyl-tRNA synthetases as novel therapeutic targets
Zymedi is a life sciences company focused on Noncatalytic regulatory roles of aminoacyl-tRNA synthetases as novel therapeutic targets.
Profile data last refreshed Yesterday
Open Jobs
0
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Placebo Cohort 1
Pulmonary Arterial Hypertension PAHClinical Trials (1)
NCT05967299Study of Intravenous ZMA001 in Healthy Subjects
Phase 1Help build intelligence for Zymedi
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.